Feasibility of a Novel Process-based Treatment for Patients With Psychosis (PROBAS)
Schizophrenia, Schizotypal Disorder, Delusional Disorder
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Psychosis spectrum disorder, Process-based therapy, Modular psychotherapy, Group Therapy, Acceptance and Commitment Therapy (ACT), Metacognitive Training (MCT)
Eligibility Criteria
Inclusion Criteria:
- Main diagnosis of a mental disorder with psychotic symptoms according to ICD-10 criteria currently experiencing delusions and hallucinations (F20, F21, F22, F23, F24, F25, F28, F29, F30.2, F31.2, F31.5, F32.3, F33.3) indicated by diagnostic assessment of attending MD
- Age between 18 and 70 years
- Informed consent to the study procedures and assessments (in written form)
Exclusion Criteria:
- Severe neurological or internal concomitant diseases
- IQ < 80; severe learning disability, brain damage or pervasive developmental disorder
- Missing eligibility for psychotherapy because of missing language skills/hostile or uncooperative behaviour.
No further constraints will be imposed in order to collect data in a representative clinical sample.
Sites / Locations
- Max Planck Institute of Psychiatry
Arms of the Study
Arm 1
Experimental
Metacognitive and Defusion Training
All participating patients are allocated to the same five-week experimental group therapy, which consists of three different modules (Module I: Psychoeducation on cognitive processes and rational of the therapy - week 1; Module II: Metacognition - week 2+3; Module III: Cognitive Defusion - week 4+5). Group therapy will start with a psychoeducation session of 60 minutes in the first week and will then take place twice a week with each session lasting 60 minutes.